PASSIVE iShares Nasdaq US Biotechnology UCITS BTEE ETF U.S. Dollar (Distributing) iShares IV plc February 2025 Performance, Portfolio Breakdowns and Net Asset information as at: 28-Feb-2025. All other data as at 07-Mar-2025. This document is marketing material. For Investors in the UK. Investors should read the KIID/PRIIPs document and prospectus prior to investing, and should refer to the prospectus for the funds full list of risks. FUND OVERVIEW PRODUCT INFORMATION The iShares Nasdaq US Biotechnology UCITS ETF seeks to track the investment results of an ISIN : IE00BDZVHG35 index composed of biotechnology and pharmaceutical equities listed on the NASDAQ. Share Class Launch Date : 05-Mar-2018 KEY BENEFITS Share Class Currency : USD 1.Diversified exposure to U.S. biotechnology and pharmaceutical companies. Total Expense Ratio : 0.35% 2.Targeted access to biotechnology and pharmaceutical stocks listed on the NASDAQ. Use of Income : Distributing 3.Use to express a sector view. Net Assets of Share Class (M) : 29.43 USD KEY FACTS RISK INDICATOR Asset Class : Equity Lower Risk Higher RiskBenchmark : Nasdaq Biotechnology Index(R) Potentially Lower RewardsPotentially Higher Rewards Fund Launch Date : 19-Oct-2017 Distribution Frequency : Semi-Annual Net Assets of Fund (M) : 523.01 USD12 34567 SFDR Classification : Other CAPITAL AT RISK: The value of investments and the income from them can fall as well as rise Domicile : Ireland and are not guaranteed. Investors may not get back the amount originally invested. Methodology : Replicated KEY RISKS: Issuing Company : iShares IV plc Investment risk is concentrated in specific sectors, countries, currencies or companies.Product Structure : Physical This means the Fund is more sensitive to any localised economic, market, political, sustainability-related or regulatory events.ISA Eligibility : Yes The value of equities and equity-related securities can be affected by daily stock market SIPP Available : Yes movements. Other influential factors include political, economic news, company UK Reporting Status : Yes earnings and significant corporate events. Counterparty Risk: The insolvency of any institutions providing services such asPORTFOLIO CHARACTERISTICS safekeeping of assets or acting as counterparty to derivatives or other instruments, may expose the Share Class to financial loss. 12m Trailing Yield : 0.44% Price to Book Ratio : 3.69x Price to Earnings Ratio : 24.68x 3y Beta : 1.00 Number of Holdings : 266 iShares Nasdaq US Biotechnology UCITS ETF U.S. Dollar (Distributing) iShares IV plc CALENDAR YEAR PERFORMANCE 20152016 2017 2018201920202021 2022 2023 2024 Share Class- - - - 24.59 25.91 -0.40 -10.534.22 -0.96 Benchmark - - - - 24.90 26.20 -0.18 -10.364.33 -0.81 GROWTH OF HYPOTHETICAL 10,000 USD SINCE INCEPTION CUMULATIVE & ANNUALISED PERFORMANCE CUMULATIVE (%) ANNUALISED (% p.a.)1m 3m 6m YTD 1y 3y 5ySince Inception Share Class -0.21 -2.60 -7.27 4.91 2.45 4.615.11 4.09 Benchmark -0.22 -2.57 -7.19 4.92 2.61 4.785.30 4.29 The figures shown relate to past performance. Past performance is not a reliable indicator of current or future performance and should not be the sole factor of consideration when selecting a product or strategy. Share Class and Benchmark performance displayed in USD, hedged share class benchmark performance is displayed in USD. Performance is shown on a Net Asset Value (NAV) basis, with gross income reinvested where applicable. The return of your investment may increase or decrease as a result of currency fluctuations if your investment is made in a currency other than that used in the past performance calculation. Source: BlackRockShare Class iShares Nasdaq US Biotechnology UCITS ETF U.S. Dollar (Distributing)Benchmark Nasdaq Biotechnology Index(R) Contact Us For EMEA: +353 1 612 3394 • www.blackrock.com • investor.services@blackrock.com iShares Nasdaq US Biotechnology UCITS ETF U.S. Dollar (Distributing) iShares IV plc TOP 10 HOLDINGS (%) GILEAD SCIENCES INC 10.19% AMGEN INC 8.99% VERTEX PHARMACEUTICALS INC8.46% REGENERON PHARMACEUTICALS INC 7.20% ASTRAZENECA ADR REPRESENTING .5 PL4.23% ALNYLAM PHARMACEUTICALS INC 3.04% BIOGEN INC1.95% ARGENX SE ADR 1.92% SANOFI ADR REPRESENTING SA1.56% SUMMIT THERAPEUTICS INC 1.46% Total of Portfolio 49.00% Holdings are subject to change. SECTOR BREAKDOWN (%) Fund Allocations are subject to change. Source: BlackRockTRADING INFORMATION Exchange London Stock Exchange Ticker BTEE Bloomberg Ticker BTEE LN RICBTEE.L SEDOL BDZVHG3 Listing Currency USD Contact Us For EMEA: +353 1 612 3394 • www.blackrock.com • investor.services@blackrock.com iShares Nasdaq US Biotechnology UCITS ETF U.S. Dollar (Distributing) iShares IV plc GLOSSARY SFDR Classification: Article 8: Products that promote environmental Price to Book Ratio: represents the ratio of the current closing price of or social characteristics and promote good governance practices. the share to the latest quarter's book value per share. Article 9: Products that have sustainable investments as an objective and follow good governance practices. Other: Products that do not meet the criteria to be classified as Article 8 or 9. Price to Earnings: A valuation ratio of a company's current share price compared to its per-share earnings in the current forecast year, calculated as current share price divided by current earnings per share. IMPORTANT INFORMATION: In the UK and Non-European Economic Area (EEA) countries: This is issued by BlackRock Advisors (UK) Limited, which is authorised and regulated by the Financial Conduct Authority. Registered office: 12 Throgmorton Avenue, London, EC2N 2DL, Tel: +44 (0)20 7743 3000. Registered in England and Wales No. 00796793. For your protection, calls are usually recorded. Please refer to the Financial Conduct Authority website for a list of authorised activities conducted by BlackRock. iShares plc, iShares II plc, iShares III plc, iShares IV plc, iShares V plc, iShares VI plc and iShares VII plc (together 'the Companies') are open-ended investment companies with variable capital having segregated liability between their funds organised under the laws of Ireland and authorised by the Central Bank of Ireland. Further information about the Fund and the Share Class, such as details of the key underlying investments of the Share Class and share prices, is available on the iShares website at www.ishares.com or by calling +44 (0)845 357 7000 or from your broker or financial adviser. The indicative intra-day net asset value of the Share Class is available at http://deutsche-boerse.com and/or http://www.reuters.com. A UCITS ETF’s units / shares that have been acquired on the secondary market cannot usually be sold directly back to the UCITS ETF itself. Investors who are not Authorised Participants must buy and sell shares on a secondary market with the assistance of an intermediary (e.g. a stockbroker) and may incur fees and additional taxes in doing so. In addition, as the market price at which the Shares are traded on the secondary market may differ from the Net Asset Value per Share, investors may pay more than the then current Net Asset Value per Share when buying shares and may receive less than the current Net Asset Value per Share when selling them. For investors in the UK: This document is marketing material. This document is intended for information purposes only and does not constitute investment advice or an offer to sell or a solicitation of an offer to buy the products described within and no steps may be taken which would constitute or result in a public offering in the UK. This document is strictly confidential and may not be distributed without authorisation from BlackRock Advisors (UK) Limited. Any decision to invest must be based solely on the information contained in the Prospectus, Base Prospectus, Key Investor Information Document, Key Information Document and the latest half-yearly report and unaudited accounts and/or annual report and audited accounts which are available at www.ishares.com in English. Investors should read the specific risks in the Key Investor Information Document, the Key Information Document the Prospectus and the Base Prospectus. BlackRock may terminate marketing at any time. Capital at risk: Past performance is not a reliable indicator of current or future results and should not be the sole factor of consideration when selecting a product or strategy. Changes in the rates of exchange between currencies may cause the value of investments to diminish or increase. Fluctuation may be particularly marked in the case of a higher volatility fund and the value of an investment may fall suddenly and substantially. Levels and basis of taxation may change from time to time. BlackRock has not considered the suitability of this investment against your individual needs and risk tolerance. The data displayed provides summary information. Investment should be made on the basis of the relevant Prospectus which is available from the manager. The products mentioned in this document are intended for information purposes only and do not constitute investment advice or an offer to sell or a solicitation of an offer to buy the securities described within. This document may not be distributed without authorisation from BlackRock. Restricted Investors: This document is not, and under no circumstances is to be construed as an advertisement or any other step in furtherance of a public offering of shares in the United States or Canada. This document is not aimed at persons who are resident in the United States, Canada or any province or territory thereof, where the companies/securities are not authorised or registered for distribution and where no prospectus has been filed with any securities commission or regulatory authority. The companies/securities may not be acquired or owned by, or acquired with the assets of, an ERISA Plan. Nasdaq®', 'Nasdaq-100®' and 'Nasdaq-100 Index®' are trademarks of the Nasdaq Stock Market Inc. (which with its affiliates is referred to as the 'Corporations') and are licensed for use by BlackRock Asset Management Deutschland AG. iShares NASDAQ-100® (DE) is not issued, endorsed, sold or promoted by the Corporations. The Corporations make no warranties and bear no liability with respect to the Product. Any research in this document has been procured and may have been acted on by BlackRock for its own purpose. The results of such research are being made available only incidentally. The views expressed do not constitute investment or any other advice and are subject to change. They do not necessarily reflect the views of any company in the BlackRock Group or any part thereof and no assurances are made as to their accuracy. © 2025 BlackRock, Inc. All Rights reserved. BLACKROCK, BLACKROCK SOLUTIONS and iSHARES are trademarks of BlackRock, Inc. or its subsidiaries in the United States and elsewhere. All other trademarks are those of their respective owners. Contact Us For EMEA: +353 1 612 3394 • www.blackrock.com • investor.services@blackrock.com